Laevoroc Oncology is Drug Discovery in Switzerland that focus on Provider business. Founded in 2019. They cover business area such as Provider, cancer therapeutic technology, innovation, cancer treatment, an oral gemcitabine prodrug, maintenance therapy, pancreatic, ovarian and breast cancer, a molecule, receptor activation, relapsed leukemia, allogeneic stem cell transplantation, medical practitioner, patient.
2019
( 5 years old in 2024 )
Provider
-
Boesch 37
6331 Hünenberg
Switzerland
Private
Providercancer therapeutic technologyinnovationcancer treatmentan oral gemcitabine prodrugmaintenance therapypancreatic, ovarian and breast cancera moleculereceptor activationrelapsed leukemiaallogeneic stem cell transplantationmedical practitionerpatient
* We use standard office opening hours in near Laevoroc Oncology's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Laevoroc Oncology is Drug Discovery business from Switzerland that founded in 2019 (5 years old in 2024), Laevoroc Oncology business is focusing on Provider.
Laevoroc Oncology headquarter office and corporate office address is located in Boesch 37 6331 Hünenberg Switzerland.
Laevoroc Oncology was founded in Switzerland.
In 2024, Laevoroc Oncology is currently focus on Provider sector.
Above is snippet of Google Trends for "Provider" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Laevoroc Oncology, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
